Nirsevimab Effective In Protecting Infants Against RSV-Associated LRTD, Study Finds

HealthDay (7/30, Gotkine) reports a study found that “nirsevimab is effective for protecting infants against respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD).” For the study, the researchers “identified 35 and 462 RSV LRTD episodes among nirsevimab-immunized infants and nonimmunized infants. Nirsevimab effectiveness was 87.2, 98.0, and 71.0 percent against RSV LRTD, hospitalized RSV LRTD, and PCR-confirmed RSV, respectively. Fewer encounters and lower odds of hospitalization were seen for nirsevimab-immunized infants with RSV LRTD than nonimmunized infants.” The study was published in Pediatrics.